Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.

Abstract

Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.

• Authors: Ismail Simsek, Salih Pay, Ayhan Dinc, Hakan Erdem, Bulent Kurt
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 26 Issue 9 Pg. 1561-2 (Sep 2007) ISSN: 0770-3198 [Print] Germany
• PMID: 17061154 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Etanercept

Topics

• Adult
• Antibodies, Monoclonal (adverse effects)
• Carcinoid Tumor (chemically induced)
• Etanercept
• Humans
• Immunoglobulin G (adverse effects)
• Male
• Pituitary ACTH Hypersecretion (etiology)
• Receptors, Tumor Necrosis Factor
• Spondylarthritis (drug therapy)
• Thymus Neoplasms (chemically induced)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)